[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 112
Citations 0
Comment & Response
February 2, 2017

Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema—Reply

Author Affiliations
  • 1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Editor, JAMA Ophthalmology
  • 3Jaeb Center for Health Research, Tampa, Florida
  • 4Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor
  • 5Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor
  • 6College of Engineering, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor
JAMA Ophthalmol. Published online February 2, 2017. doi:10.1001/jamaophthalmol.2016.5686

In Reply We thank Messori and Clark et al for their letters. Messori asked us to comment on whether treatment-related adverse events cost more for repackaged (compounded) bevacizumab, which does not have regulatory approval for intravitreous use. He emphasized that the medicolegal aspects of treatment-related adverse events have become increasingly expensive from a malpractice perspective, and he is concerned about isolated clusters of endophthalmitis events that were due to errors in repackaging.

First Page Preview View Large
First page PDF preview
First page PDF preview